Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT02407405Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by National Cancer Institute. Started Jan 2016; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT02407405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407405.